{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:35:16Z","timestamp":1792607716792,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009367","name":"Mansoura University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009367","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Toxoplasmosis treatments are currently limited due to their ineffectiveness against the chronic stage and potential adverse effects. The search for novel medications that possess characteristics such as non-toxicity, and efficacy on all stages of the parasite, particularly the cystic form, is important. The <jats:italic>n<\/jats:italic>-butanol (<jats:italic>n<\/jats:italic>-BuOH) fraction of <jats:italic>Cycas rumphii<\/jats:italic> has shown promising potency against <jats:italic>Toxoplasma gondii<\/jats:italic> (RH strain) in vitro, and this study aimed to evaluate its efficacy against <jats:italic>T. gondii<\/jats:italic> in mice models. Therefore, mice were infected with 20 cysts (acute infection model) or 10 cysts (chronic infection model) of <jats:italic>T. gondii<\/jats:italic> (ME49 strain). The infected mice were treated with <jats:italic>C. rumphii n<\/jats:italic>-BuOH fraction and cotrimoxazole at 200\u00a0mg\/kg\/day and 370\u00a0mg\/kg\/day, respectively, divided into 2 doses\/12\u00a0h, starting the 4th day (acute stage) or the 6th week (chronic model) post-infection, and continued for 14 consecutive days. Mice were sacrificed at 56, and 70 days post-infection for acute and chronic models, respectively, to assess the efficacy of treatment. Evaluations included size and count of brain cysts, histopathological examinations of the brain and liver, inflammatory scoring, and immunological studies to assess the levels of nitric oxide (NO), interferon-gamma (INF-\u03b3), and tumor necrosis factor-alpha (TNF-\u03b1) in serum. Oral administration of the <jats:italic>n<\/jats:italic>-BuOH fraction at a daily dose of 200\u00a0mg\/kg for two weeks significantly reduced the cyst count in the brains of infected mice and improved the survival rate. The results were comparable to those observed in subgroups treated with cotrimoxazole in both acute and chronic models. The histopathological findings indicated that <jats:italic>C. rumphii n<\/jats:italic>-BuOH alleviated <jats:italic>T. gondii<\/jats:italic>-induced brain and liver lesions. Furthermore, the serum levels of NO, and IFN-\u03b3 were significantly elevated in the <jats:italic>C. rumphii n<\/jats:italic>-BuOH fraction-treated subgroups. High-performance liquid chromatography analysis indicated that this fraction is rich in phenolic acids, including caffeic acid, gallic acid, and chlorogenic acid which have been linked to anti-oxidant, anti-inflammatory, antiparasitic, and anti-<jats:italic>Toxoplasma<\/jats:italic> properties. Experimental results demonstrated that the <jats:italic>n<\/jats:italic>-BuOH fraction of <jats:italic>C. rumphii<\/jats:italic> exhibits anti-<jats:italic>Toxoplasma<\/jats:italic> effects, making it a promising candidate for the development of complementary therapies or use in combination with other drugs.<\/jats:p>","DOI":"10.1038\/s41598-025-98993-y","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T12:50:50Z","timestamp":1746449450000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Phytochemical content of Cycas rumphii n-butanol fraction and antiprotozoal activity against Toxoplasma gondii in vivo"],"prefix":"10.1038","volume":"15","author":[{"given":"Hosam M.","family":"El-Seadawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amany E.","family":"Ragab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"El-Aasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamilia A. Abo","family":"El-Seoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayat A.","family":"Elblihy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El-Sayed","family":"El-Alfy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan Abd","family":"Elgawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somaya","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"Sheta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Elseadawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"98993_CR1","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/S0020-7519(00)00124-7","volume":"30","author":"AM Tenter","year":"2000","unstructured":"Tenter, A. M., Heckeroth, A. R. & Weiss, L. M. Toxoplasma gondii: from animals to humans. Int. J. Parasitol. 30, 1217\u20131258. https:\/\/doi.org\/10.1016\/S0020-7519(00)00124-7 (2000).","journal-title":"Int. J. Parasitol."},{"key":"98993_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1079\/AHR2005100","volume":"6","author":"DE Hill","year":"2005","unstructured":"Hill, D. E., Chirukandoth, S. & Dubey, J. P. Biology and epidemiology of Toxoplasma gondii in man and animals. Anim. Health Res. Rev. 6, 41\u201361. https:\/\/doi.org\/10.1079\/AHR2005100 (2005).","journal-title":"Anim. Health Res. Rev."},{"key":"98993_CR3","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1550-7408.2008.00345.x","volume":"55","author":"JP Dubey","year":"2008","unstructured":"Dubey, J. P. The history of Toxoplasma gondii\u2013the first 100 years. J. Eukaryot. Microbiol. 55, 467\u2013475. https:\/\/doi.org\/10.1111\/j.1550-7408.2008.00345.x (2008).","journal-title":"J. Eukaryot. Microbiol."},{"key":"98993_CR4","doi-asserted-by":"publisher","unstructured":"Dubey, J. P. Toxoplasmosis of animals and humans. 2nd edition, CRC press. (2010). https:\/\/doi.org\/10.1201\/9781420092370","DOI":"10.1201\/9781420092370"},{"key":"98993_CR5","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1080\/10408398.2017.1352563","volume":"58","author":"S Belluco","year":"2018","unstructured":"Belluco, S., Simonato, G., Mancin, M., Pietrobelli, M. & Ricci, A. Toxoplasma gondii infection and food consumption: A systematic review and meta-analysis of case-controlled studies. Crit. Rev. Food Sci. Nutr. 58, 3085\u20133096. https:\/\/doi.org\/10.1080\/10408398.2017.1352563 (2018).","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"98993_CR6","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.rvsc.2020.10.019","volume":"135","author":"S Almeria","year":"2021","unstructured":"Almeria, S. & Dubey, J. P. Foodborne transmission of Toxoplasma gondii infection in the last decade. An overview. Res. J. Vet. Sci. 135, 371\u2013385. https:\/\/doi.org\/10.1016\/j.rvsc.2020.10.019 (2021).","journal-title":"Res. J. Vet. Sci."},{"key":"98993_CR7","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/j.1469-0691.2008.02091.x","volume":"14","author":"F Derouin","year":"2008","unstructured":"Derouin, F., Pelloux, H. & ESCMID Study Group on Clinical Parasitology. Prevention of toxoplasmosis in transplant patients. CMI 14, 1089\u20131101. https:\/\/doi.org\/10.1111\/j.1469-0691.2008.02091.x (2008).","journal-title":"CMI"},{"key":"98993_CR8","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.2217\/fmb.09.89","volume":"4","author":"VL Pereira-Chioccola","year":"2009","unstructured":"Pereira-Chioccola, V. L., Vidal, J. E. & Su, C. Toxoplasma gondii infection and cerebral toxoplasmosis in HIV-infected patients. Future Microbiol. 4, 1363\u20131379. https:\/\/doi.org\/10.2217\/fmb.09.89 (2009).","journal-title":"Future Microbiol."},{"key":"98993_CR9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/00006254-200105000-00025","volume":"56","author":"JL Jones","year":"2001","unstructured":"Jones, J. L., Lopez, A., Wilson, M., Schulkin, J. & Gibbs, R. Congenital toxoplasmosis: A review. Obstet. Gynecol. Surv. 56, 296\u2013305 (2001).","journal-title":"Obstet. Gynecol. Surv."},{"key":"98993_CR10","doi-asserted-by":"publisher","first-page":"e00037","DOI":"10.1016\/j.fawpar.2019.e00037","volume":"15","author":"S Stelzer","year":"2019","unstructured":"Stelzer, S. et al. Toxoplasma gondii infection and toxoplasmosis in farm animals: risk factors and economic impact. Food Waterborne Parasitol. 15, e00037. https:\/\/doi.org\/10.1016\/j.fawpar.2019.e00037 (2019).","journal-title":"Food Waterborne Parasitol."},{"key":"98993_CR11","doi-asserted-by":"publisher","unstructured":"Nayeri, T., Sarvi, S., Moosazadeh, M. & Daryani, A. Global prevalence of Toxoplasma gondii infection in the aborted fetuses and ruminants that had an abortion: A systematic review and meta-analysis. Vet. Parasitol. 290, e109370 (2021). https:\/\/doi.org\/10.1016\/j.vetpar.2021.109370 Get rights and content.","DOI":"10.1016\/j.vetpar.2021.109370"},{"key":"98993_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.imlet.2017.03.006","volume":"185","author":"E Ahmadpour","year":"2017","unstructured":"Ahmadpour, E. et al. Enhancing immune responses to a DNA vaccine encoding Toxoplasma gondii GRA14 by calcium phosphate nanoparticles as an adjuvant. Immunol. Lett. 185, 40\u201347. https:\/\/doi.org\/10.1016\/j.imlet.2017.03.006 (2017).","journal-title":"Immunol. Lett."},{"key":"98993_CR13","doi-asserted-by":"publisher","first-page":"e00036","DOI":"10.1016\/j.fawpar.2019.e00036","volume":"15","author":"N Konstantinovic","year":"2019","unstructured":"Konstantinovic, N., Guegan, H., St\u00e4jner, T., Belaz, S. & Robert-Gangneux, F. Treatment of toxoplasmosis: current options and future perspectives. Food Waterborne Parasitol. 15, e00036. https:\/\/doi.org\/10.1016\/j.fawpar.2019.e00036 (2019).","journal-title":"Food Waterborne Parasitol."},{"key":"98993_CR14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1017\/S0031182019001604","volume":"147","author":"L Nishi","year":"2020","unstructured":"Nishi, L. et al. Rosuvastatin reduced brain parasite burden in a chronic toxoplasmosis in vivo model and influenced the neuropathological pattern of ME-49 strain. Parasitol 147, 303\u2013309. https:\/\/doi.org\/10.1017\/S0031182019001604 (2020).","journal-title":"Parasitol"},{"key":"98993_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/cmr.00057-17","volume":"31","author":"IR Dunay","year":"2018","unstructured":"Dunay, I. R., Gajurel, K., Dhakal, R., Liesenfeld, O. & Montoya, J. G. Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice. Cli Microb. Rev. 31, 10\u20131128. https:\/\/doi.org\/10.1128\/cmr.00057-17 (2018).","journal-title":"Cli Microb. Rev."},{"key":"98993_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/DDDT.S60973","volume":"11","author":"PH Alday","year":"2017","unstructured":"Alday, P. H. & Doggett, J. S. Drugs in development for toxoplasmosis: advances, challenges, and current status. Drug Des. Devel Ther. 11, 273\u2013293 (2017).","journal-title":"Drug Des. Devel Ther."},{"key":"98993_CR17","doi-asserted-by":"publisher","first-page":"e0138204","DOI":"10.1371\/journal.pone.0138204","volume":"10","author":"HX Wei","year":"2015","unstructured":"Wei, H. X., Wei, S. S., Lindsay, D. S. & Peng, H. J. A systematic review and meta-analysis of the efficacy of anti-Toxoplasma gondii medicines in humans. PloS One. 10, e0138204. https:\/\/doi.org\/10.1371\/journal.pone.0138204 (2015).","journal-title":"PloS One"},{"key":"98993_CR18","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.ijantimicag.2008.04.012","volume":"32","author":"KM Choi","year":"2008","unstructured":"Choi, K. M., Gang, J. & &Yun, J. Anti-Toxoplasma gondii RH strain activity of herbal extracts used in traditional medicine. Int. J. Antimicrob. Agents. 32, 360\u2013362. https:\/\/doi.org\/10.1016\/j.ijantimicag.2008.04.012 (2008).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"98993_CR19","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1139\/cjpp-2016-0039","volume":"94","author":"M Sharif","year":"2016","unstructured":"Sharif, M. et al. The efficacy of herbal medicines against Toxoplasma gondii during the last 3 decades: a systematic review. Can. J. Physiol. Pharmacol. 94, 1237\u20131248. https:\/\/doi.org\/10.1139\/cjpp-2016-0039 (2016).","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"98993_CR20","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s11686-020-00300-4","volume":"66","author":"K Cheraghipour","year":"2021","unstructured":"Cheraghipour, K. et al. The experimental role of medicinal plants in treatment of Toxoplasma gondii infection: a systematic review. Acta Parasitol. 66, 303\u2013328. https:\/\/doi.org\/10.1007\/s11686-020-00300-4 (2021).","journal-title":"Acta Parasitol."},{"key":"98993_CR21","unstructured":"Calonje, M., Stevenson, D. W. & Osborne, R. The World List of Cycads, online edition. (2013\u20132024). http:\/\/www.cycadlist.org [accessed 21 October 2024]."},{"key":"98993_CR22","volume-title":"The cycads, first ed","author":"LM Whitelock","year":"2002","unstructured":"Whitelock, L. M. The Cycads, First Ed (Timber, 2002)."},{"key":"98993_CR23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.7751\/telopea20095826","volume":"12","author":"AJ Lindstrom","year":"2009","unstructured":"Lindstrom, A. J., Hill, K. D. & Stanberg, L. C. The genus Cycas (Cycadaceae) in Indonesia. Telopea 12, 385\u2013418 (2009).","journal-title":"Telopea"},{"key":"98993_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3897\/phytokeys.102.24380","volume":"102","author":"RA DeFilipps","year":"2018","unstructured":"DeFilipps, R. A. & Krupnick, G. A. The medicinal plants of Myanmar. PhytoKeys 102, 1\u2013341. https:\/\/doi.org\/10.3897\/phytokeys.102.24380 (2018).","journal-title":"PhytoKeys"},{"key":"98993_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/0378-8741(95)01259-G","volume":"47","author":"MT Kowalska","year":"1995","unstructured":"Kowalska, M. T., Itzhak, Y. & &Puett, D. Presence of aromatase inhibitors in cycads. J. Ethnopharmacol. 47, 113\u2013116. https:\/\/doi.org\/10.1016\/0378-8741(95)01259-G (1995).","journal-title":"J. Ethnopharmacol."},{"key":"98993_CR26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3923\/jm.2011.761.768","volume":"6","author":"AV Khan","year":"2011","unstructured":"Khan, A. V., Ahmed, Q. U., Khan, A. A. & Shukla, I. Antibacterial activity of Cycas rumphii Miq. Leaves extracts against some tropical human pathogenic bacteria. Res. J. Microbiol. 6, 761\u2013768 (2011).","journal-title":"Res. J. Microbiol."},{"key":"98993_CR27","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.3390\/plants11212867","volume":"11","author":"HM El-Seadawy","year":"2022","unstructured":"El-Seadawy, H. M., El-Seoud, A., El-Aasr, K. A., Tawfik, M., Ragab, A. E. & H. O. & Toxoplasmocidal and cytotoxic activities guided isolation and characterization of an undescribed Bioflavonoid-di-C-glucoside from Cycas rumphii Miq. Cultivated Egypt. Plants. 11, 2867. https:\/\/doi.org\/10.3390\/plants11212867 (2022).","journal-title":"Cultivated Egypt. Plants"},{"key":"98993_CR28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2478\/s11535-012-0107-3","volume":"8","author":"E Attard","year":"2013","unstructured":"Attard, E. A rapid microtitre plate Folin-Ciocalteu method for the assessment of polyphenols. Open. Life Sci. 8, 48\u201353 (2013).","journal-title":"Open. Life Sci."},{"key":"98993_CR29","first-page":"254","volume":"2","author":"M Kiranmai","year":"2011","unstructured":"Kiranmai, M., Kumar, C. M. & Mohammed, I. Comparison of total flavanoid content of Azadirachta indica root bark extracts prepared by different methods of extraction. Res. J. Pharm. Biol. Chem. Sci. 2, 254\u2013261 (2011).","journal-title":"Res. J. Pharm. Biol. Chem. Sci."},{"key":"98993_CR30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.exppara.2018.10.003","volume":"195","author":"NL El-Tantawy","year":"2018","unstructured":"El-Tantawy, N. L. et al. Could Araucaria heterophylla resin extract be used as a new treatment for toxoplasmosis? Exp. Parasitol. 195, 44\u201353. https:\/\/doi.org\/10.1016\/j.exppara.2018.10.003 (2018).","journal-title":"Exp. Parasitol."},{"key":"98993_CR31","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1080\/01913123.2021.1984349","volume":"45","author":"MS Elmehankar","year":"2021","unstructured":"Elmehankar, M. S., Elhenawy, A. A., Aboukamar, W. A., Elzoheiry, M. A. & Nabih, N. Histopathological and ultrastructural assessment of atovaquone-proguanil hydrochloride combination in chronic murine toxoplasmosis. Ultrastruct Pathol. 45, 376\u2013383. https:\/\/doi.org\/10.1080\/01913123.2021.1984349 (2021).","journal-title":"Ultrastruct Pathol."},{"key":"98993_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/0471142735.im1903s96","volume":"96","author":"C Subauste","year":"2012","unstructured":"Subauste, C. & Hubal, A. Animal models for Toxoplasma gondii infection. Curr. Protoc. Immunol. 96, 19\u201313. https:\/\/doi.org\/10.1002\/0471142735.im1903s96 (2012).","journal-title":"Curr. Protoc. Immunol."},{"key":"98993_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.actatropica.2019.04.013","volume":"195","author":"SI El-Kowrany","year":"2019","unstructured":"El-Kowrany, S. I., Abd El Ghaffar, A. E. S., Shoheib, Z. S., Mady, R. F. & Gamea, G. A. M. Evaluation of Nitazoxanide as a novel drug for the treatment of acute and chronic toxoplasmosis. Acta Trop. 195, 145\u2013154. https:\/\/doi.org\/10.1016\/j.actatropica.2019.04.013 (2019).","journal-title":"Acta Trop."},{"key":"98993_CR34","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1007\/s00436-016-5041-2","volume":"115","author":"MA Eraky","year":"2016","unstructured":"Eraky, M. A., El-Fakahany, A. F., El-Sayed, N. M., Abou-Ouf, E. A. R. & Yaseen, D. I. Effects of Thymus vulgaris ethanolic extract on chronic toxoplasmosis in a mouse model. Parasitol. Res. 115, 2863\u20132871. https:\/\/doi.org\/10.1007\/s00436-016-5041-2 (2016).","journal-title":"Parasitol. Res."},{"key":"98993_CR35","doi-asserted-by":"publisher","first-page":"e106810","DOI":"10.1016\/j.actatropica.2022.106810","volume":"239","author":"BM El Sharazly","year":"2023","unstructured":"El Sharazly, B. M. et al. Mefloquine loaded niosomes as a promising approach for the treatment of acute and chronic toxoplasmosis. Acta Trop. 239, e106810. https:\/\/doi.org\/10.1016\/j.actatropica.2022.106810 (2023).","journal-title":"Acta Trop."},{"key":"98993_CR36","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1097\/00000478-199512000-00007","volume":"19","author":"KP Batts","year":"1995","unstructured":"Batts, K. P. & Ludwig, J. An update on terminology and reporting. Am. J. Surg. Pathol. 19, 1409\u20131417 (1995).","journal-title":"Am. J. Surg. Pathol."},{"key":"98993_CR37","doi-asserted-by":"publisher","first-page":"e107756","DOI":"10.1016\/j.exppara.2019.107756","volume":"206","author":"H Abd Elgawad","year":"2019","unstructured":"Abd Elgawad, H. et al. Biological evaluation of newly synthesized quinoline\u2013based compound PPQ-8 in acute and chronic toxoplasmosis: an experimental study. Exp. Parasitol. 206, e107756. https:\/\/doi.org\/10.1016\/j.exppara.2019.107756 (2019).","journal-title":"Exp. Parasitol."},{"key":"98993_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/cmr.00115-19","volume":"34","author":"HM Elsheikha","year":"2020","unstructured":"Elsheikha, H. M., Marra, C. M., Zhu, X. Q. & Epidemiology pathophysiology, diagnosis, and management of cerebral toxoplasmosis. Clin. Microbiol. Rev. 34, 10\u20131128. https:\/\/doi.org\/10.1128\/cmr.00115-19 (2020).","journal-title":"Clin. Microbiol. Rev."},{"key":"98993_CR39","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.biopha.2016.05.041","volume":"82","author":"M Antczak","year":"2016","unstructured":"Antczak, M., Dzitko, K. & D\u0142ugo\u0144ska, H. Human toxoplasmosis\u2013Searching for novel chemotherapeutics. Biomed. Pharmacother. 82, 677\u2013684. https:\/\/doi.org\/10.1016\/j.biopha.2016.05.041 (2016).","journal-title":"Biomed. Pharmacother."},{"key":"98993_CR40","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/j.ophtha.2005.05.025","volume":"112","author":"M Soheilian","year":"2005","unstructured":"Soheilian, M. et al. Prospective randomized trial of Trimethoprim\/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology 112, 1876\u20131882. https:\/\/doi.org\/10.1016\/j.ophtha.2005.05.025 (2005).","journal-title":"Ophthalmology"},{"key":"98993_CR41","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1179\/2047773213Y.0000000094","volume":"107","author":"S Rajapakse","year":"2013","unstructured":"Rajapakse, S. et al. Antibiotics for human toxoplasmosis: a systematic review of randomized trials. Pathog Glob Health. 107, 162\u2013169. https:\/\/doi.org\/10.1179\/2047773213Y.0000000094 (2013).","journal-title":"Pathog Glob Health"},{"key":"98993_CR42","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/hiv.12402","volume":"18","author":"AV Hernandez","year":"2017","unstructured":"Hernandez, A. V. et al. A systematic review and meta\u2010analysis of the relative efficacy and safety of treatment regimens for HIV\u2010associated cerebral toxoplasmosis: is trimethoprim\u2010sulfamethoxazole a real option? HIV Med. 18, 115\u2013124. https:\/\/doi.org\/10.1111\/hiv.12402 (2017).","journal-title":"HIV Med."},{"key":"98993_CR43","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1093\/cid\/ciac645","volume":"76","author":"C Prosty","year":"2023","unstructured":"Prosty, C. et al. Revisiting the evidence base for modern-day practice of the treatment of Toxoplasmic encephalitis: a systematic review and meta-analysis. Clin. Infect. Dis. 76, 1302\u20131319. https:\/\/doi.org\/10.1093\/cid\/ciac645 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"98993_CR44","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1503\/cmaj.111152","volume":"183","author":"JMW Ho","year":"2011","unstructured":"Ho, J. M. W. Juurlink & D.N. Considerations when prescribing trimethoprim\u2013sulfamethoxazole. Cmaj 183, 1851\u20131858. https:\/\/doi.org\/10.1503\/cmaj.111152 (2011).","journal-title":"Cmaj"},{"key":"98993_CR45","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1097\/INF.0000000000002664","volume":"39","author":"RM Burgos","year":"2020","unstructured":"Burgos, R. M., Reynolds, K. M., Williams, J., Li, W. & Yan, C. H. Trimethoprim-Sulfamethoxazole associated drug-induced liver injury in pediatrics: A systematic review. J. Pediat Infect. Dis. 39, 824\u2013829. https:\/\/doi.org\/10.1097\/INF.0000000000002664 (2020).","journal-title":"J. Pediat Infect. Dis."},{"key":"98993_CR46","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S0020-7519(98)00023-X","volume":"28","author":"JP Dubey","year":"1998","unstructured":"Dubey, J. P. Advances in the life cycle of Toxoplasma gondii. Int. J. Parasitol. 28, 1019\u20131024. https:\/\/doi.org\/10.1016\/S0020-7519(98)00023-X (1998).","journal-title":"Int. J. Parasitol."},{"key":"98993_CR47","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1128\/mmbr.00027-15","volume":"79","author":"KJ Pittman","year":"2015","unstructured":"Pittman, K. J. & Knoll, L. J. Long-term relationships: the complicated interplay between the host and the developmental stages of Toxoplasma gondii during acute and chronic infections. Microbiol. Mol. Biol. Rev. 79, 387\u2013401. https:\/\/doi.org\/10.1128\/mmbr.00027-15 (2015).","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"98993_CR48","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.exppara.2017.01.009","volume":"174","author":"P Saraf","year":"2017","unstructured":"Saraf, P., Shwab, E. K., Dubey, J. P. & Su, C. On the determination of Toxoplasma gondii virulence in mice. Exp. Parasitol. 174, 25\u201330. https:\/\/doi.org\/10.1016\/j.exppara.2017.01.009 (2017).","journal-title":"Exp. Parasitol."},{"key":"98993_CR49","doi-asserted-by":"publisher","unstructured":"Wang, Q. & Sibley, L. D. Assays for monitoring Toxoplasma gondii infectivity in the laboratory mouse. In: Toxoplasma gondii. Methods in Molecular Biology, Vol. 2071 (ed. Tonkin, C.) 99\u2013116. https:\/\/doi.org\/10.1007\/978-1-4939-9857-9_5 (Humana, New York, 2020).","DOI":"10.1007\/978-1-4939-9857-9_5"},{"key":"98993_CR50","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.exppara.2018.12.003","volume":"196","author":"GF Watson","year":"2019","unstructured":"Watson, G. F. & Davis, P. H. Systematic review and meta-analysis of variation in Toxoplasma gondii cyst burden in the murine model. Exp. Parasitol. 196, 55\u201362. https:\/\/doi.org\/10.1016\/j.exppara.2018.12.003 (2019).","journal-title":"Exp. Parasitol."},{"key":"98993_CR51","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/jac\/dkf251","volume":"50","author":"O Djurkovi\u0107-Djakovi\u0107","year":"2002","unstructured":"Djurkovi\u0107-Djakovi\u0107, O., Milenkovi\u0107, V., Nikoli\u0107, A., Bobi\u0107, B. & Gruji\u0107, J. Efficacy of Atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii. J. Antimicrob. Chemother. 50, 981\u2013987. https:\/\/doi.org\/10.1093\/jac\/dkf251 (2002).","journal-title":"J. Antimicrob. Chemother."},{"key":"98993_CR52","doi-asserted-by":"publisher","first-page":"e0156255","DOI":"10.1371\/journal.pone.0156255","volume":"11","author":"JP Dubey","year":"2016","unstructured":"Dubey, J. P. et al. Experimental toxoplasmosis in rats induced orally with eleven strains of Toxoplasma gondii of seven genotypes: tissue tropism, tissue cyst size, neural lesions, tissue cyst rupture without reactivation, and ocular lesions. PloS One. 11, e0156255. https:\/\/doi.org\/10.1371\/journal.pone.0156255 (2016).","journal-title":"PloS One"},{"key":"98993_CR53","doi-asserted-by":"publisher","first-page":"6361","DOI":"10.1038\/s41598-017-06610-4","volume":"7","author":"JH Kim","year":"2017","unstructured":"Kim, J. H. et al. NADPH oxidase 4 is required for the generation of macrophage migration inhibitory factor and host defense against Toxoplasma gondii infection. Sci. Rep. 7, 6361. https:\/\/doi.org\/10.1038\/s41598-017-06610-4 (2017).","journal-title":"Sci. Rep."},{"key":"98993_CR54","doi-asserted-by":"publisher","first-page":"e202300132","DOI":"10.1002\/cmdc.202300132","volume":"18","author":"TA Khan","year":"2023","unstructured":"Khan, T. A. et al. Evaluation of the antiparasitic and antifungal activities of synthetic Piperlongumine-Type cinnamide derivatives: booster effect by halogen substituents. ChemMedChem 18, e202300132. https:\/\/doi.org\/10.1002\/cmdc.202300132 (2023).","journal-title":"ChemMedChem"},{"key":"98993_CR55","doi-asserted-by":"publisher","first-page":"e684393","DOI":"10.3389\/fcell.2021.684393","volume":"9","author":"J Zhang","year":"2021","unstructured":"Zhang, J. et al. Licarin-B exhibits activity against the Toxoplasma gondii RH strain by damaging mitochondria and activating autophagy. Front. Cell. Dev. Biol. 9, e684393. https:\/\/doi.org\/10.3389\/fcell.2021.684393 (2021).","journal-title":"Front. Cell. Dev. Biol."},{"key":"98993_CR56","doi-asserted-by":"publisher","first-page":"e104891","DOI":"10.1016\/j.bse.2024.104891","volume":"117","author":"O El Faqer","year":"2024","unstructured":"El Faqer, O. et al. Pharmacological insights into Laurus nobilis: HPLC profiling and evaluation of its anti-Toxoplasma, antioxidant, and anti-hemolytic properties. Biochem. Syst. Ecol. 117, e104891. https:\/\/doi.org\/10.1016\/j.bse.2024.104891 (2024).","journal-title":"Biochem. Syst. Ecol."},{"key":"98993_CR57","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1128\/aac.50.4.1352-1364.2006","volume":"50","author":"D Tasdemir","year":"2006","unstructured":"Tasdemir, D. et al. Antitrypanosomal and antileishmanial activities of flavonoids and their analogues: in vitro, in vivo, structure-activity relationship, and quantitative structure-activity relationship studies. Antimicrob. Agents Chemother. 50, 1352\u20131364. https:\/\/doi.org\/10.1128\/aac.50.4.1352-1364.2006 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"98993_CR58","doi-asserted-by":"publisher","unstructured":"Sharaf-El-Deen, S., Soliman, S. & Brakat, R. Evaluation of the antiparasitic and antifibrotic effects of Gallic acid on experimental hepatic schistosomiasis mansoni. J. Helminthol. 98 https:\/\/doi.org\/10.1017\/S0022149X23000937 (2024).","DOI":"10.1017\/S0022149X23000937"},{"key":"98993_CR59","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1080\/10715760400016139","volume":"38","author":"FM Da Cunha","year":"2004","unstructured":"Da Cunha, F. M. et al. Caffeic acid derivatives: in vitro and in vivo anti-inflammatory properties. Free Radic Res. 38, 1241\u20131253. https:\/\/doi.org\/10.1080\/10715760400016139 (2004).","journal-title":"Free Radic Res."},{"key":"98993_CR60","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2174\/138955711796268750","volume":"11","author":"M Touaibia","year":"2011","unstructured":"Touaibia, M., Jean-Francois, J. & Doiron, J. Caffeic acid, a versatile pharmacophore: an overview. Mini-Rev Med. Chem. 11, 695\u2013713. https:\/\/doi.org\/10.2174\/138955711796268750 (2011).","journal-title":"Mini-Rev Med. Chem."},{"key":"98993_CR61","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.3892\/etm.2015.2346","volume":"9","author":"F Armutcu","year":"2015","unstructured":"Armutcu, F., Akyol, S., Ustunsoy, S. & Turan, F. F. Therapeutic potential of caffeic acid phenethyl ester and its anti-inflammatory and Immunomodulatory effects. Exp. Ther. Med. 9, 1582\u20131588. https:\/\/doi.org\/10.3892\/etm.2015.2346 (2015).","journal-title":"Exp. Ther. Med."},{"key":"98993_CR62","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.jfda.2016.05.003","volume":"24","author":"FA Khan","year":"2016","unstructured":"Khan, F. A., Maalik, A. & Murtaza, G. Inhibitory mechanism against oxidative stress of caffeic acid. JFDA 24, 695\u2013702. https:\/\/doi.org\/10.1016\/j.jfda.2016.05.003 (2016).","journal-title":"JFDA"},{"key":"98993_CR63","doi-asserted-by":"publisher","first-page":"74","DOI":"10.31989\/bchd.v3i4.692","volume":"3","author":"A Birkov\u00e1","year":"2020","unstructured":"Birkov\u00e1, A., Hubkov\u00e1, B., Boler\u00e1zska, B., Marekov\u00e1, M. & \u010ci\u017em\u00e1rov\u00e1, B. Caffeic acid: A brief overview of its presence, metabolism, and bioactivity. BCHD 3, 74\u201381 (2020).","journal-title":"BCHD"},{"key":"98993_CR64","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/nu8010016","volume":"8","author":"N Liang","year":"2015","unstructured":"Liang, N. & Kitts, D. D. Role of chlorogenic acids in controlling oxidative and inflammatory stress conditions. Nutr 8, 16. https:\/\/doi.org\/10.3390\/nu8010016 (2015).","journal-title":"Nutr"},{"key":"98993_CR65","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.biopha.2017.10.064","volume":"97","author":"M Naveed","year":"2018","unstructured":"Naveed, M. et al. Chlorogenic acid (CGA): A Pharmacological review and call for further research. Biomed. Pharmacother. 97, 67\u201374. https:\/\/doi.org\/10.1016\/j.biopha.2017.10.064 (2018).","journal-title":"Biomed. Pharmacother."},{"key":"98993_CR66","doi-asserted-by":"publisher","first-page":"225","DOI":"10.22038\/ijbms.2019.32806.7897","volume":"22","author":"N Kahkeshani","year":"2019","unstructured":"Kahkeshani, N. et al. Pharmacological effects of Gallic acid in health and diseases: A mechanistic review. Iran. J. Basic. Med. Sci. 22, 225\u2013237. https:\/\/doi.org\/10.22038\/ijbms.2019.32806.7897 (2019).","journal-title":"J. Basic. Med. Sci."},{"key":"98993_CR67","doi-asserted-by":"publisher","unstructured":"Bai, J. et al. Gallic acid: Pharmacological activities and molecular mechanisms involved in inflammation-related diseases. Biomedicine & pharmacotherapy.133, e110985 (2021). https:\/\/doi.org\/10.1016\/j.biopha.2020.110985","DOI":"10.1016\/j.biopha.2020.110985"},{"key":"98993_CR68","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3389\/fimmu.2018.00158","volume":"9","author":"YS Hwang","year":"2018","unstructured":"Hwang, Y. S. et al. Characteristics of infection immunity regulated by Toxoplasma gondii to maintain chronic infection in the brain. Front. Immunol. 9, 158. https:\/\/doi.org\/10.3389\/fimmu.2018.00158 (2018).","journal-title":"Front. Immunol."},{"key":"98993_CR69","doi-asserted-by":"publisher","first-page":"e580425","DOI":"10.3389\/fcimb.2020.580425","volume":"10","author":"D Mukhopadhyay","year":"2020","unstructured":"Mukhopadhyay, D., Arranz-Sol\u00eds, D. & Saeij, J. P. Influence of the host and parasite strain on the immune response during Toxoplasma infection. Front. Cell. Infect. Microbiol. 10, e580425. https:\/\/doi.org\/10.3389\/fcimb.2020.580425 (2020).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"98993_CR70","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/S0020-7519(03)00092-4","volume":"33","author":"CG L\u00fcder","year":"2003","unstructured":"L\u00fcder, C. G., Algner, M., Lang, C., Bleicher, N. & Gro\u03b2, U. Reduced expression of the inducible nitric oxide synthase after infection with Toxoplasma gondii facilitates parasite replication in activated murine macrophages. Int. J. Parasitol. 33, 833\u2013844. https:\/\/doi.org\/10.1016\/S0020-7519(03)00092-4 (2003).","journal-title":"Int. J. Parasitol."},{"key":"98993_CR71","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/intimm\/dxy004","volume":"30","author":"M Sasai","year":"2018","unstructured":"Sasai, M., Pradipta, A. & Yamamoto, M. Host immune responses to Toxoplasma gondii. Int. Immunol. 30, 113\u2013119. https:\/\/doi.org\/10.1093\/intimm\/dxy004 (2018).","journal-title":"Int. Immunol."},{"key":"98993_CR72","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.pt.2011.03.009","volume":"27","author":"R Pifer","year":"2011","unstructured":"Pifer, R. & Yarovinsky, F. Innate responses to Toxoplasma gondii in mice and humans. Trends Parasitol. 27, 388\u2013393 (2011).","journal-title":"Trends Parasitol."},{"key":"98993_CR73","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/nrmicro2858","volume":"10","author":"CA Hunter","year":"2012","unstructured":"Hunter, C. A. & Sibley, L. D. Modulation of innate immunity by Toxoplasma gondii virulence effectors. Nat. Rev. Microbiol. 10, 766\u2013778. https:\/\/doi.org\/10.1038\/nrmicro2858 (2012).","journal-title":"Nat. Rev. Microbiol."},{"key":"98993_CR74","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1128\/iai.01722-14","volume":"82","author":"CR Sturge","year":"2014","unstructured":"Sturge, C. R. & Yarovinsky, F. Complex immune cell interplay in the gamma interferon response during Toxoplasma gondii infection. Infect. Immun. 82, 3090\u20133097. https:\/\/doi.org\/10.1128\/iai.01722-14 (2014).","journal-title":"Infect. Immun."},{"key":"98993_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21608\/PUJ.2024.247259.1230","volume":"17","author":"A Elblihy","year":"2024","unstructured":"Elblihy, A. et al. Insights on the therapeutic effect of quinolone-based compound, PPQ-8 plus Nitazoxanide, in chronic toxoplasmosis murine model. PUJ 17, 1\u20139. https:\/\/doi.org\/10.21608\/PUJ.2024.247259.1230 (2024).","journal-title":"PUJ"},{"key":"98993_CR76","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00281-012-0339-3","volume":"34","author":"CD Dupont","year":"2012","unstructured":"Dupont, C. D., Christian, D. A. & Hunter, C. A. Immune response and immunopathology during toxoplasmosis. Springer Semin. Immunopathol 34, 793\u2013813. https:\/\/doi.org\/10.1007\/s00281-012-0339-3 (2012).","journal-title":"Immunopathol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98993-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98993-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98993-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T12:50:52Z","timestamp":1746449452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98993-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["98993"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-98993-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]},"assertion":[{"value":"28 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15697"}}